|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||79.40 - 79.75|
|52 Week Range||62.88 - 80.44|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||23.19|
|Earnings Date||Apr 26, 2019|
|Forward Dividend & Yield||3.07 (3.92%)|
|1y Target Est||82.62|
Pharmaceuticals group Sanofi is working on a plan to find a new CEO in agreement and consultation with current chief executive Olivier Brandicourt, a spokesman for the French drugmaker told Reuters on Monday. Sanofi has an age limit of 65 for its CEO. Brandicourt will be 65 in February 2021.
March 15, 2019 - The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors. ASCVD is an umbrella term, defined as a build-up of plaque in the arteries that can lead to reduced blood flow and a number of serious conditions such as stroke, peripheral artery disease and acute coronary syndrome (ACS), which includes heart attack and unstable angina.
Sanofi successfully prices EUR 2 billion of bond issues Paris, France - March 13, 2019 - Sanofi announces that it has successfully priced its offering of EUR 2 billion of notes (the " Notes ") ...
The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs. Shares of Regeneron closed up 2.3 percent at $412.05 on Monday. The FDA first approved the drug in 2017 and it has since been launched as a treatment for adults with moderate-to-severe atopic dermatitis, or eczema, as well as a drug for some asthma patients.
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids. "For the first time, adolescents with uncontrolled moderate-to-severe atopic dermatitis have an approved biologic treatment option to help control persistent, often debilitating symptoms such as chronic itch and widespread rash.
The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs. The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.
On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report PARIS, France - March 8, 2019 ...
March 8, 2019 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (CRSwNP). Patients with severe CRSwNP often experience recurrence despite previous treatment with surgery and/or systemic corticosteroids.
Olivier Brandicourt has been the CEO of Sanofi (EPA:SAN) since 2015. This analysis aims first to contrast CEO compensation with other large companies. Next, we'll consider growth that the businessRead More...
Biotech stocks had a fairly decent outing in February, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) adding roughly 2.7 percent for the month compared to the 3 percent gain for the S&P 500 ...
March 1, 2019 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® (dupilumab), recommending its approval in the European Union for use in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised FeNO who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment. The positive CHMP opinion is based on clinical data from 2,888 adults and adolescents who participated in three pivotal trials from the global LIBERTY ASTHMA program, including the Phase 3 QUEST and VENTURE trials. QUEST compared Dupixent vs. placebo in asthma patients inadequately controlled on a medium or high dose inhaled corticosteroid and a second controller medication. VENTURE compared Dupixent vs. placebo in oral corticosteroid dependent asthma patients. The European Commission is expected to make a final decision on the application for Dupixent in the coming months.
March 1, 2019 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Marketing Authorization of ZynquistaTM* (sotagliflozin), developed by Sanofi and Lexicon. The CHMP recommended approval of sotagliflozin in the European Union (EU) in both a 200-mg and 400-mg dose for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes (T1D) mellitus with a body mass index = 27 kg/m2, who have failed to achieve adequate glycemic control despite optimal insulin therapy.
The Philippine Department of Justice said on Friday it had found probable cause to indict officials from French drugmaker Sanofi and former and current Philippine health officials over a series of deaths related to a dengue vaccine. It recommended that six Sanofi officials and 14 current and former Philippine health officials be charged, including former health minister Janette Garin. Sanofi could not immediately be reached for comment.
BRIDGEWATER, N.J., Feb. 27, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL. Previously approved for use as an add-on to diet and exercise in adults with type 2 diabetes who are uncontrolled on long-acting insulin or lixisenatide, Soliqua 100/33 can now also be prescribed for patients uncontrolled on oral antidiabetic medicines. "Many people living with type 2 diabetes are uncontrolled on diet and exercise alone and could require additional interventions to help lower their blood sugar levels," said Michelle Carnahan, North America Head of Primary Care, Sanofi.
Republican Senators John Cornyn and Chuck Grassley said on Tuesday that they would support the powerful Senate Judiciary committee if the panel were to examine the patent system under which drug companies ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
Senate Finance Committee Chairman Chuck Grassley invites seven drugmakers to testify about drug prices. Executives from seven pharmaceutical companies — AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi — will testify Tuesday before the Senate Finance Committee.